<DOC>
	<DOCNO>NCT00044291</DOCNO>
	<brief_summary>The purpose study determine whether first line combination hormonal therapy experimental drug , atamestane , plus FDA-approved drug , toremifene ( Fareston® ) , effective another approve drug , letrozole ( Femara® ) , delay growth breast cancer postmenopausal patient locally advance metastatic breast cancer , whether side effect combination different side effect letrozole .</brief_summary>
	<brief_title>Phase III Study Atamestane Plus Toremifene Versus Letrozole Advanced Breast Cancer</brief_title>
	<detailed_description>Breast cancer cell often dependent estrogen continue grow . Atamestane block formation estrogens androgenic precursor body . Toremifene block circulate intracellular estrogen stimulate estrogen receptor breast cancer cell . The goal therapy atamestane , aromatase inhibitor , combination estrogen receptor antagonist , toremifene , achieve maximal suppression estrogen stimulation breast cancer cell . This study design determine whether combination therapy lengthen time disease progression rate objective response compare single agent aromatase inhibitor therapy letrozole .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Hormone-Dependent</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Estrogen Receptor Modulators</mesh_term>
	<mesh_term>Atamestane</mesh_term>
	<criteria>Women age 18 year old Pathological histological confirmation breast cancer initial diagnosis time metastases ECOG performance status 0 , 1 2 Karnofsky performance status 60 high Predicted life expectancy 12 week Postmenopausal endocrine status . LH/FSH level postmenopausal range woman whose menopause occur less 5 year ago Locally recurrent , locally advanced , locally metastatic disease amenable radiation therapy surgery and/or distant metastatic disease At least one tumor localization measurable 2 dimension ( one diameter least 2 cm soft tissue/visceral disease assess CT/MRI scan conventional Xray technique , one diameter least 1 cm bone lesion assess conventional Xray technique ) Estrogen receptor and/or progesterone receptor positive ( laboratory/institutional standard ) time initial diagnosis determine subsequent biopsy/surgery metastasis Written inform consent obtain Prior hormonal therapy treat locally recurrent , locally advanced metastatic disease Prior adjuvant therapy aromatase inhibitor antiestrogens/SERMs within 12 month prior enrollment Progression disease therapy antiestrogens ( include SERMs administer prevention osteoporosis ) Lifethreatening locally recurrent , locally advanced metastatic disease disease require chemotherapeutic intervention ( inflammatory breast cancer ) History know CNS metastasis , significant neurological dysfunction include active seizure , clinical sign significant neurological disease Other active malignancy ( except basal cell carcinoma skin situ cervical cancer ) . Patients previous malignancy must without evidence disease least five year Renal insufficiency ( serum creatinine &gt; 2.0 mg/dL ) Aspartate aminotransferase , alanine aminotransferase serum bilirubin level 2.5 time upper limit normal Hemoglobin &lt; 9 g/dL Platelet count le 100,000 platelet per mm3 Total white blood cell count le 2,000 cell per mm3 Premenopausal endocrine status ; pregnant lactating female Usage investigational drug within thirty ( 30 ) day prior enrollment ; plan usage investigational drug study medication course current study Contraindication use toremifene , atamestane , letrozole inactive component formulation Prior enrollment study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Atamestane</keyword>
	<keyword>Toremifene</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>Receptor-positive</keyword>
	<keyword>First line therapy</keyword>
	<keyword>Estrogen blocker</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Locally advanced breast cancer</keyword>
	<keyword>Locally recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>ductal breast carcinoma</keyword>
	<keyword>lobular breast carcinoma</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>